JAK/STAT signaling by cytokine receptors

Current Opinion in Immunology

Volumn 10, Issue 3, 1998, Pages 271-278

  Liu, Kathleen D ^a   Gaffen, Sarah L ^a   Goldsmith, Mark A ^a,b  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; TRANSCRIPTION FACTOR;

CELL GROWTH; CELL SURVIVAL; GENE DELETION; NEGATIVE FEEDBACK; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031805248     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80165-9     Document Type: Article

References (80)

1. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415-1421.
2. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol. 12:1996;91-128.
3. Shuai K, Horvath CM, Huang LHT, Qureshi SA, Cowburn D, Darnell JE. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 76:1994;821-828.
4. Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J. 16:1997;7067-7077.
5. Schindler C, Darnell JE. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem. 64:1995;621-651.
6. Azam M, Erdjument-Bromage H, Kreider BL, Xia M, Quelle F, Basu R, Saris C, Tempst P, Ihle JN, Schindler C. Interleukin-3 signals through multiple forms of Stat5. EMBO J. 14:1995;1402-1411.
7. Mui AL-F, Wakao H, O'Farrell A-M, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 14:1995;1166-1175.
8. Shuai K, Stark GR, Kerr IM, Darnell JE. Polypeptide signaling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature. 366:1993;580-583.
9. Silvennoinen O, Ihle JN, Schlessinger J, Levy DE. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature. 366:1993;583-585.
10. Shuai K, Stark GR, Kerr IM, Darnell JE. A single phosphotyrosine residue of Stat91 required for gene activation by inteferon-γ Science. 261:1993;1744-1746.
11. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell. 85:1996;149-158.
12. Liu KD, Gaffen SL, Goldsmith MA, Greene WC. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are diffenentially regulated by tyrosine phosphorylation. of special interest Curr Biol. 7:1997;817-826 This paper, together with Gauzzi et al., 1996 [13] and Feng et al., 1997 [14], defines the role of activation loop tyrosine residues in Janus kinases, with the surprising observation that, while Jak1, Jak2 and Tyk2 all require at least one of these residues for catalytic function, in Jak3 these residues are dispensable.
13. Gauzzi MC, Velazquez L, McKendry R, Mogensen KE, Fellous M, Pellegrini S. Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. of special interest J Biol Chem. 271:1996;20494-20500 This paper, together with Liu et al., 1997 [12] and Feng et al., 1997 [14], defines the role of activation loop tyrosine residues in Janus kinases, with the surprising observation that, while Jak1, Jak2 and Tyk2 all require at least one of these residues for catalytic function, in Jak3 these residues are dispensable.
14. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN. Activation of JAK2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. of special interest Mol Cell Biol. 17:1997;2497-2501 This paper, together with Liu et al., 1997 [12] and Gauzzi et al., 1996 [13], defines the role of activation loop tyrosine residues in Janus kinases, with the surprising observation that, while Jak1, Jak2 and Tyk2 all require at least one of these residues for catalytic function, in Jak3 these residues are dispensable.
15. Lee C-K, Bluyssen HAR, Levy DE. Regulation of interferon-α responsiveness by the duration of Janus kinase activity. J Biol Chem. 272:1997;21872-21877.
16. Gaffen SL, Lai SY, Xu W, Gouilleux F, Groner B, Goldsmith MA, Greene WC. Signaling through the IL-2R β chain activates a STAT-5-like DNA binding activity. Proc Natl Acad Sci USA. 92:1995;7192-7196.
17. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 16:1996;6985-6992.
18. Yin T, Shen R, Geng G-S, Yang Y-C. Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinase. J Biol Chem. 272:1997;1032-1037.
19. Haspel RL, Salditt-Georgieff M, Darnell JE. The rapid inactivation of nuclear tyrosine phosphorylated STAT1 depends upon a protein tyrosine phosphatase. of special interest EMBO J. 15:1996;6262-6268 This is a particularly carefully performed study examining the turnover and nuclear import and export of Stat-1 in interferon-induced cells, in which the authors demonstrate convincingly that the majority of Stat-1 protein is recycled out of the nucleus rather than being degraded by proteasomes. Moreover, they perform a complete kinetic analysis of the duration of the interferon-induced response.
20. Kim TK, Maniatis T. Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteasome pathway. Science. 273:1996;1717-1719.
21. Aragane Y, Kulms D, Luger TA, Schwartz T. Down-regulation of interferon γ-activated STAT1 by UV light. Proc Natl Acad Sci USA. 94:1997;11490-11495.
22. Starr R, Willson TA, Viney EM, Murray LJL, Rayner RR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. A family of cytokine-inducible inhibitors of signalling. of special interest Nature. 387:1997;917-921 Collectively, Starr et al., Naka et al., 1997 [23], Endo et al., 1997 [24] and Chung et al., 1997 [26] provide the first evidence for a negative feedback loop controlling JAK/STAT responses, and identify new families of negative regulatory proteins involved in cytokine signaling.
23. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al. Structure and function of a new STAT-induced STAT inhibitor. of special interest Nature. 387:1997;924-928 Collectively, Naka et al., Starr et al., 1997 [22], Endo et al., 1997 [24] and Chung et al., 1997 [26] provide the first evidence for a negative feedback loop controlling JAK/STAT responses, and identify new families of negative regulatory proteins involved in cytokine signaling.
24. Endo TA, Masahura M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al. A new protein containing an SH2 domain that inhibits JAK kinases. of special interest Nature. 387:1997;921-924 Collectively, Endo et al., Starr et al., 1997 [22], Naka et al., 1997 [23] and Chung et al., 1997 [26] provide the first evidence for a negative feedback loop controlling JAK/STAT responses, and identify new families of negative regulatory proteins involved in cytokine signaling.
25. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes and SH2-containing protein that binds to tyrosine-phosphorylated interleukin 2 and erythropoietin receptors. EMBO J. 14:1995;2816-2826.
26. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. of special interest Science. 278:1997;1803-1805 Collectively, Chung et al., Starr et al., 197 [22], Naka et al., 1997 [23] and Endo et al., 1997 [24] provide the first evidence for a negative feedback loop controlling JAK/STAT responses, and identify new families of negative regulatory proteins involved in cytokine signaling.
27. Nosaka T, van Deursen JMA, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN. Defective lymphoid development in mice lacking Jack. Science. 270:1995;800-802.
28. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, Miyakie K, Nakauchi H, Shirasawa T, Saito T. Developmental defects of lymphoid cells in JAK3 kinase-deficient mice. Immunity. 3:1995;771-782.
29. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 270:1995;794-797.
30. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, Drago J, Noguchi M, Grinberg A, Bloom ET, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity. 2:1995;223-238.
31. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc Natl Acad Sci USA. 92:1995;377-381.
32. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ. Mutation of JAK3 gene in patients with autosomal severe iombined immune defiency (SCID). Nature. 377:1995;65-68.
33. Russell SM, Tayebi N, Nakajima H, Reidy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science. 270:1995;797-799.
34. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 73:1993;147-157.
35. Liu KD, Lai SY, Goldsmith MA, Greene WC. Identification of a variable region within the cytoplasmic tail of the IL-2 receptor β chain that is required for growth signal transduction. J Biol Chem. 270:1995;22176-22181.
36. Thomis DC, Berg LJ. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med. 185:1997;197-206.
37. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 94:1997;3801-3804.
38. Akira S, Nishio Y, Inoue M, Wang X-J, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 77:1994;63-71.
39. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AJ, Wilks AF, Yasukawa K, Taga T, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 263:1994;89-92.
40. Ruff-Jamison S, Chen K, Cohen S. Induction by EGF and Interferon-γ of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. Science. 261:1993;1733-1736.
41. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, Lai C-F, Tartaglia LA. The full-length leptin receptor has signaling capabilities of interleukin 6 -type receptors. Proc Natl Acad Sci USA. 93:1996;8374-8378.
42. of special interest Liu X, Robinson GW, Wagner K, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. of outstanding interest Gen Dev. 11:1997;179-186 Udy et al., 1997 [43] and this paper report knockouts that further illustrate the surprising selectivity of STATs in vivo as compared with their widespread activation by diverse cytokine receptors observed in cultured cells (see annotation to Durbin et al., 1996 [45] and Meraz et al., 1996 [46]).
43. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park S-H, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. of special interest Proc Natl Acad Sci USA. 94:1997;7239-7244 Liu et al., 1997 [42] and this paper report knockouts that further illustrate the surprising selectivity of STATs in vivo as compared with their widespread activation by diverse cytokine receptors observed in cultured cells (see annotation to Durbin et al., 1996 [45] and Meraz et al., 1996 [46]).
44. Nakajima H, Liu X-W, Wynshaw-Boris A, Rosenthal LA, Imada K, Finbloom DS, Hennighausen L, Leonard WJ. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor α chain induction. Immunity. 7:1997;691-701.
45. -/- animals was in the interferon system, despite the widespread activation of Stat-1 in cultured cells.
46. -/- animals was in the interferon system, despite the widespread activation of Stat-1 in cultured cells.
47. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 382:1996;171-174.
48. Kaplan M, Sun Y, Hoey T, Grusby M. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 382:1996;174-177.
49. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S. Essential role of Stat6 in IL-4 signalling. Nature. 380:1996;627-630.
50. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Vignali DAA, Doherty PC, Grosveld G, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 380:1996;630-633.
51. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity. 4:1996;313-319.
52. Kopf M, LeGros G, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 362:1993;245-248.
53. Magram J, Sfarra J, Connaughton S, Faherty D, Warrier R, Carvajal D, Wu CY, Stewart C, Sarmiento U, Gately MK. IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann NY Acad Sci. 795:1996;60-70.
54. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G, Leonard WJ. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 269:1995;79-81.
55. Yu C-L, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. Science. 269:1995;81-83.
56. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science. 269:1995;1875-1877.
57. Zong C, Yan R, August A, Darnell JE, Hanafusa H. Unique signal transduction of Eyk: Constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J. 15:1996;4515-4525.
58. Yu C-L, Jove R, Burakoff SJ. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol. 159:1997;5206-5210.
59. Lund TC, Garcia R, Medveczky MM, Jove R, Medveczky PG. Activation of STAT transcription factors by Herpesvirus Saimiri Tip-484 requires p56-Ick. J Virol. 71:1997;6677-6682.
60. Binari R, Perrimon N. Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila. Gen Dev. 8:1994;300-312.
61. Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 14:1995;2857-2865.
62. Luo H, Hanratty WP, Dearolf CR. An amino acid substitution in the Drosophila hop-Tum-1 Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 14:1995;1412-1420.
63. Yan R, Small S, Desplan C, Dearolf CR, Darnell JE. Identification of a Stat gene that functions in Drosophila development. Cell. 84:1996;421-430.
64. Hou XS, Melnick MB, Perrimon N. Marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs. Cell. 84:1996;411-419.
65. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. of outstanding interest Science. 278:1997;1309-1312 This is the first example of a likely causative role for JAKs in human cancer.
66. WAF1/CIP1 and show that this gene can be induced by interferon signaling.
67. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science. 278:1997;1630-1632.
68. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE. Transcriptionally active Stat1 is required for the antiproliferative effects of both IFN-α and IFN-γ Proc Natl Acad Sci USA. 93:1996;7673-7678.
69. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu X-Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 17:1997;5328-5337.
70. Vignais M, Sadowski H, Watling D, Rogers N, Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 16:1996;1759-1769.
71. Sadowski HB, Gilman MZ. Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature. 362:1993;79-83.
72. Marrero MB, Schieffer B, Paxton W, Heerdt L, Berk B, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature. 375:1995;247-250.
73. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the AT1A receptor activates transcription factor-Stat91 and/or a related protein. J Biol Chem. 269:1994;31443-31449.
74. Stöcklin E, Wisller M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 383:1996;726-728.
75. Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM, Rose DW, Rosenfeld MG, Glass CK. Nuclear integration of JAK/STAT and Ras/AP-1 signalling by CBP and p300. Proc Natl Acad Sci USA. 94:1997;1074-1079.
76. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc Natl Acad Sci USA. 93:1995;15092-15096.
77. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Yang CH. STAT3 as an adaptor to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. of special interest Science. 276:1997;1418-1420 The findings in this paper demonstrate that STATs may function not only as transcription factors but also as adaptor molecules. In this case, Stat-3 links phosphatidylinositol 3-kinase to the IFN receptor.
78. Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. of special interest Oncogene. 14:1997;751-761 While the predominant paradigm for STAT activation suggests that STATs bind to phosphorylated tyrosine residues on the activating receptor, this paper demonstrates that in some instances STATs may be delivered to the receptor complex by binding to JAKs instead. This explains some previous observations that certain receptors can activate STATs even in the absence of receptor tyrosine residues.
79. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity. 6:1997;379-387.
80. Fusaki N, Iwamatsu A, Iwashima M, Fujisawa J-I. Interaction between Sam68 and src family tyrosine kinases, fyn and lck, in T cell receptor signaling. J Biol Chem. 272:1997;6214-6219.